Referenzen Ozempic® Semaglutid FAQ

Auf dieser Seite finden Sie eine ausführliche Liste der wissenschaftlichen Referenzen, die für die Artikel in unserem FAQ-Bereich über Ozempic® (Semaglutid) verwendet wurden. Diese Quellen wurden sorgfältig aus renommierten Datenbanken wie PubMed und anderen wissenschaftlichen Plattformen ausgewählt. Die Referenzen stammen aus führenden medizinischen Fachzeitschriften, wissenschaftlichen Veröffentlichungen und offiziellen Gebrauchsinformationen. Sie bieten einen fundierten Einblick in die Wirksamkeit, Sicherheit und Anwendung von Ozempic® beim Gewichtsmanagement.

1. Obesity, cardiovascular disease, and the promising role of semaglutide: insights from the SELECT trial (2024). Current Problems in Cardiology. Verfügbar unter: https://www.sciencedirect.com/science/article/pii/S0146280623004772

2. Medications for obesity: A review (2024). Journal of the American Medical Association. Verfügbar unter: https://jamanetwork.com/journals/jama/article-abstract/2821290

3. Semaglutide and Tirzepatide Use and Reduction of Cardiovascular Risks in Adults with Overweight and Obesity (2024). Medical Research Archives. Verfügbar unter: https://esmed.org/MRA/mra/article/view/5714

4. Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study (2024). Obesity Science & Practice. Verfügbar unter: https://onlinelibrary.wiley.com/doi/abs/10.1002/osp4.762

5. One-year weight reduction with semaglutide or liraglutide in clinical practice (2024). JAMA Network Open. Verfügbar unter: https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2823644

6. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (2024). Diabetologia. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11153294/

7. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (2024). British Medical Journal. Verfügbar unter: https://www.bmj.com/content/384/bmj-2023-076410.long

8. Productkenmerken (2024). Novo Nordisk. Verfügbar unter: https://www.novo-pi.com/ozempic.pdf#guide

9. Wegovy, Werkzame stof: semaglutide (2024). Apotheek.nl. Verfügbar unter: https://www.apotheek.nl/medicijnen/semaglutide?product=ozempic

10. Ozempic (2024). Novo Nordisk. Verfügbar unter: https://www.ozempic.com/

11. Highlights of Prescribing Information (2024). Novo Nordisk. Verfügbar unter: https://www.novo-pi.com/ozempic.pdf

12. Prikinstructies (2024). Novo Nordisk. Verfügbar unter: https://www.novomedlink.com/diabetes/products/treatments/ozempic.html

13. Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism (2024). Diabetes & Metabolism Journal. Verfügbar unter: https://www.e-dmj.org/journal/view.php?number=2843

14. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis (2024). Therapeutic Advances in Neurological Disorders. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11437580/

15. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks (2024). Obesity Pillars. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11404059/

16. Real-World Effectiveness of Semaglutide and Liraglutide for Weight Management in Overweight or Obese Adults with or Without Type-2 Diabetes Mellitus: Emulation of Randomised Clinical Trials Using UK Electronic Medical Records (2024). The Lancet. Verfügbar unter: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4785364

17. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2024). The American Journal of Cardiology. Verfügbar unter: https://www.ajconline.org/article/S0002-9149(24)00319-9/fulltext

18. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure (2024). Journal of the American College of Cardiology. Verfügbar unter: https://www.sciencedirect.com/science/article/pii/S0735109724081920?via%3Dihub

19. Semaglutide and blood pressure: an individual patient data meta-analysis (2024). European Heart Journal. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11458150/

20. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity (2024). JAMA Internal Medicine. Verfügbar unter: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080

21. Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology (2024). JAMA Internal Medicine. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11372653/

22. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (2024). Diabetes Care. Verfügbar unter: https://diabetesjournals.org/care/article/47/11/1873/156807/Efficacy-and-Safety-of-GLP-1-Medicines-for-Type-2

23. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (2024). Diabetologia. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11153294/

24. Glucagon‐like peptide‐1 receptor agonists and kidney outcomes (2024). Journal of Diabetes. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11450654/

25. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide (2024). Cardiovascular Diabetology. Verfügbar unter: https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02319-7

26. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial (2024). Nature Medicine. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11271387/

27. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022 (2024). Journal of the American Pharmacists Association. Verfügbar unter: https://www.sciencedirect.com/science/article/pii/S1544319123003096

28. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (2024). British Medical Journal. Verfügbar unter: https://www.bmj.com/content/384/bmj-2023-076410.long

29. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis (2024). Pharmacology Research. Verfügbar unter: https://www.sciencedirect.com/science/article/pii/S1043661823003870?via%3Dihub

30. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2) (2024). Journal of Clinical Endocrinology & Metabolism. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11180500/

31. Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial (2024). JMIR Research Protocols. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11437224/

32. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease (2024). Kidney International. Verfügbar unter: https://www.kidney-international.org/article/S0085-2538(24)00629-X/fulltext

33. Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective (2024). Journal Brasileiro de Nefrologia. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11548866/

34. The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review (2024). Pharmacy (Basel). Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10801460/

35. The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer (2024). Cancer Metastasis Reviews. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11554930/

36. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review (2024). International Journal of Molecular Sciences. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11050669/

37. Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations (2024). Cureus. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11456416/

38. The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review (2024). Cureus. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11410460/

39. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial (2024). Journal of the American College of Cardiology. Verfügbar unter: https://www.sciencedirect.com/science/article/pii/S0735109724081166?via%3Dihub

40. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation (2023). The Lancet. Verfügbar unter: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext

41. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (2023). Journal of the American Medical Association. Verfügbar unter: https://jamanetwork.com/journals/jama/fullarticle/2810542

42. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022 (2023). American Pharmacists Association. Verfügbar unter: https://www.sciencedirect.com/science/article/pii/S1544319123003096

43. Obesity Management in Adults: A Review (2023). Journal of the American Medical Association. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/

44. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications (2023). Life. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10144237/

45. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial (2023). Cardiovascular Diabetology. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC9960425/

46. The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF (2023). Journal of the American College of Cardiology. Verfügbar unter: https://www.sciencedirect.com/science/article/pii/S2452302X23002334

47. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues (2023). Reviews in Endocrine and Metabolic Disorders. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10697893/

48. Glucagon‐like peptide agonists: A prospective review (2023). Endocrinology, Diabetes & Metabolism. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10782143/

49. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities (2023). Current Obesity Reports. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10748770/

50. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation (2023). The Lancet. Verfügbar unter: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext

51. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis (2023). Endocrine. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10902041/

52. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (2023). Journal of the American Medical Association. Verfügbar unter: https://jamanetwork.com/journals/jama/fullarticle/2810542

53. Obesity Management in Adults A Review (2023). Journal of the American Medical Association. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC11325826/

54. Wegovy (semaglutide): a new weight loss drug for chronic weight management (2023). Journal of Investigative Medicine. Verfügbar unter: https://journals.sagepub.com/doi/abs/10.1136/jim-2021-001952

55. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials (2023). International Journal of Molecular Sciences. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC10341852/

56. Once-weekly semaglutide in adolescents with obesity (2022). New England Journal of Medicine. Verfügbar unter: https://www.nejm.org/doi/full/10.1056/NEJMoa2208601

57. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis (2022). Endocrine. Verfügbar unter: https://link.springer.com/article/10.1007/s12020-021-02945-1

58. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity (2022). JAMA Network Open. Verfügbar unter: https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2796491

59. Once-weekly semaglutide for weight management: a clinical review (2022). Journal of Pharmacy Technology. Verfügbar unter: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272494/

60. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (2022). Journal of the American Medical Association. Verfügbar unter: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790392

61. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (2022). Journal of the American Medical Association. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC8753508/

62. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review (2022). Clinical Epidemiology. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC9738168/

63. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review (2022). Therapeutic Advances in Chronic Disease. Verfügbar unter: https://pmc.ncbi.nlm.nih.gov/articles/PMC9260566/

64. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (2022). Journal of the American Medical Association. Verfügbar unter: https://jamanetwork.com/journals/jama/fullarticle/2787907

65. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (2022). JAMA Internal Medicine. Verfügbar unter: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790392

66. Clinical review of subcutaneous semaglutide for obesity (2021). Journal of Clinical Pharmacy and Therapeutics. Verfügbar unter: https://onlinelibrary.wiley.com/doi/abs/10.1111/jcpt.13574

67. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists (2021). Advances in Therapy. Verfügbar unter: https://link.springer.com/article/10.1007/s12325-021-01710-0

68. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial (2021). The Lancet. Verfügbar unter: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract

69. Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021). The New England Journal of Medicine. Verfügbar unter: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

70. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021). The New England Journal of Medicine. Verfügbar unter: https://www.nejm.org/doi/10.1056/NEJMoa2107519?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

71. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (2021). Journal of the American Medical Association. Verfügbar unter: https://jamanetwork.com/journals/jama/fullarticle/2777025

72. Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance (2020). Clinical Diabetes. Verfügbar unter: https://diabetesjournals.org/clinical/article/38/4/390/35426/Switching-Between-Glucagon-Like-Peptide-1-Receptor

Gemeinsam auf dem Weg zu einem gesünderen Leben – ärztlich begleitet und auf Ihre persönlichen Ziele abgestimmt.

Die Inhalte dieser Referenzliste dienen ausschließlich allgemeinen Informationszwecken. Die aufgeführten Artikel und Quellen basieren auf öffentlich zugänglichen wissenschaftlichen Veröffentlichungen und beziehen sich auf die Anwendung von Ozempic® und damit verbundene Behandlungen. Trotz sorgfältiger Auswahl und Zusammenstellung der Informationen empfehlen wir Ihnen, vor medizinischen Entscheidungen immer professionellen ärztlichen Rat einzuholen. BMI Care übernimmt keine Haftung für mögliche Fehler oder Unvollständigkeiten der bereitgestellten Informationen.

Weitere Hintergrundinformationen und wissenschaftliche Grundlagen finden Sie auf unserer Seite Quellen.